World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders. Part 2: Maintenance Treatment of Major Depressive Disorder-Update 2015
The DOI matches its Crossref record; 200 of the 200 references it cites were found in a registry or an index.
Abstract
These guidelines for the treatment of unipolar depressive disorders systematically review available evidence pertaining to the biological treatment of patients with major depression and produce a series of practice recommendations that are clinically and scientifically meaningful based on the available evidence. These guidelines are intended for use by all physicians assessing and treating patients with these conditions. The relevant data have been extracted primarily from various treatment guidelines and panels for depressive disorders, as well as from meta-analyses/reviews on the efficacy of antidepressant medications and other biological treatment interventions identified by a search of the MEDLINE database and Cochrane Library. The identified literature was evaluated with respect to the strength of evidence for its efficacy and was then categorized into five levels of evidence (CE A-F) and five levels of recommendation grades (RG 1-5). This second part of the WFSBP guidelines on depressive disorders covers the management of the maintenance phase treatment, and is primarily concerned with the biological treatment (including pharmacological and hormonal medications, electroconvulsive therapy and other brain stimulation treatments) of adults and also, albeit to a lesser extent, children, adolescents and older adults.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Currently, pharmacological and non-pharmacological treatments are relatively well established as having at least moderate efficacy for the short-term treatment of acute major depression (Undurraga and Baldessarini, 2012; Baldessarini, 2013; Bauer et al., 2015).”
From Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials (2016) · cites this paper as Bauer et al., 2015
In the citing paper
“Two (10%) other CPGs stated that withdrawal symptoms and relapse should be differentiated from each other when discontinuing antidepressants, but without considering the potential overlap of symptoms between these situations.3,44”
From Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review (2022) · cites this paper as [44]
In the citing paper
“only about 40% of all individuals and 49% of individuals with depressive disorders underwent electroconvulsive therapy, one of the most effective treatment options for major depressive disorder.38”
From “Nothing Hurts Less Than Being Dead”: Psychological Pain in Case Descriptions of Psychiatric Euthanasia and Assisted Suicide from the Netherlands: « Rien ne fait moins mal qu’être mort »: La douleur psychologique dans les descriptions de cas d’euthanasie et de suicide assisté psychiatrique aux Pays-Bas (2020) · cites this paper as [38]
In the citing paper
“Clinical guidelines recommend an additional 4 to 9 months of antidepressant treatment after initial response is achieved and at least 3 years of continual treatment for maintenance therapy, especially in patients who experience recurrent MDD (APA, 2010; Bauer et al., 2015).”
From Relapse prevention with levomilnacipran ER in adults with major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study (2019) · cites this paper as Bauer et al., 2015
Citations
Cites
Frank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959 · cited 1×
“A recurrence is a new episode that appears during recovery (i.e., sustained remission for XYZ days/weeks or longer following the most recent acute episode) (Frank et al. 1991; Kupfer 1993).”
BackgroundAgency for Health Care Policy and Research
Eisenberg, J. M. (1999) · Medical Care · doi:10.1097/00005650-199903000-00001 · Cited by 1,369
Three-Year Outcomes for Maintenance Therapies in Recurrent Depression
Frank, E. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810240013002 · Cited by 1,297 · cited 2×
“A subsequent additional 2-year placebocontrolled study of the patients who completed the 3-year study (Frank et al. 1990) showed that imipramine (average dose of 200 mg/day) was signifi - cantly better than placebo in preventing recurrence (Kupfer et al. 1992).”
BackgroundChange in mental health after smoking cessation: systematic review and meta-analysis
Taylor, G., McNeill, A., Girling, A., Farley, A., Lindson-Hawley, N., & Aveyard, P. (2014) · BMJ · doi:10.1136/bmj.g1151 · Cited by 1,039 · cited 1×
“Smoking cessation has latterly been shown to reduce depression risk (Taylor et al. 2014).”
BackgroundDistributed Disturbances in Brain Structure and Function in Schizophrenia
(2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.1 · Cited by 969
Delivering interventions for depression by using the internet: randomised controlled trial
Christensen, H. (2004) · BMJ · doi:10.1136/bmj.37945.566632.ee · Cited by 928 · cited 1×
“Internet based approaches are increasingly being utilized (Christensen et al. 2004).”
MethodLithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis
Cipriani, A., Hawton, K., Stockton, S., & Geddes, J. R. (2013) · BMJ · doi:10.1136/bmj.f3646 · Cited by 920 · cited 1×
“A systematic review concluded that lithium is effective in the prevention of suicide, deliberate self-harm, and death from all causes in patients with mood disorders (Cipriani et al. 2013).”
BackgroundAnderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908 · cited 2×
“…al. 2012; Schaffer et al. 2012), the British Association for Psychopharmacology guidelines for treating depressive disorders with antidepressants (Anderson et al. 2008), the Australian and New Zealand clinical practice guidelines for the treatment of depression (Ellis 2004), the NICE guidelines…”
BackgroundRecurrence after recovery from major depressive disorder during 15 years of observational follow-up
Mueller, T. I., Leon, A. C., Keller, M. B., Solomon, D. A., Endicott, J., Coryell, W., Warshaw, M., & Maser, J. D. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.7.1000 · Cited by 897 · cited 1×
“Fifty to 85% of the patients who have a major depressive episode will have another episode (Mueller et al. 1999; American Psychiatric Association 2000; Andrews 2001).”
BackgroundLithium toxicity profile: a systematic review and meta-analysis
McKnight, R. F., Adida, M., Budge, K., Stockton, S., Goodwin, G. M., & Geddes, J. R. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61516-x · Cited by 877 · cited 1×
“Among the well-established side effects of lithium treatment are reduced glomerular fi ltration rate, reduced urinary concentrating ability, hypothyroidism, hyperparathyroidism and weight gain (McKnight et al. 2012).”
BackgroundBandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854 · cited 1×
“As described by Bandelow et al. (2008), Grunze et al. (2009) and Bauer et al. (2013a), six categories of evidence (CEA to F) were used (Table I): CE A: Full evidence from controlled trials CE B: Limited positive evidence from controlled trials CE C: Evidence from uncontrolled studies or case…”
MethodSelf-citationPiet, J., & Hougaard, E. (2011) · Clinical Psychology Review · doi:10.1016/j.cpr.2011.05.002 · Cited by 807 · cited 1×
“(MBCT) (Segal et al. 2010; Piet and Hougaard 2011) and interpersonal psychotherapy (IPT) (Cuijpers et al. 2011) in this indication.”
BackgroundIncreasing Rates of Depression
Klerman, G. L. (1989) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1989.03420150079041 · Cited by 779 · cited 1×
“Patients with an early onset and older adults suffering an initial depressive episode after the age of 60 appear to be at greater risk for the development of chronicity (Klerman and Weissman 1989).”
BackgroundJudd, L. L., Akiskal, H. S., Maser, J. D., Zeller, P. J., Endicott, J., Coryell, W., Paulus, M. P., Kunovac, J. L., Leon, A. C., Mueller, T. I., et al. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.8.694 · Cited by 775 · cited 1×
“The long-term course of MDD is not only characterized by high rates of recurrence but also dominated by prolonged symptomatic chronicity (Judd 1997; Judd et al. 1998).”
BackgroundBrent, D., Emslie, G., Clarke, G., Wagner, K. D., Asarnow, J. R., Keller, M., Vitiello, B., Ritz, L., Iyengar, S., Abebe, K., et al. (2008) · JAMA · doi:10.1001/jama.299.8.901 · Cited by 700 · cited 1×
“In recent years several studies have been performed to examine effi - cacy of antidepressants and their potential to prevent new depressive episodes after remission or response in children and adolescents (Brent et al. 2008; Cheung et al. 2008; Emslie et al. 2008).”
BackgroundRush, A. J., George, M. S., Sackeim, H. A., Marangell, L. B., Husain, M. M., Giller, C., Nahas, Z., Haines, S., Simpson, R. K., & Goodman, R. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00304-2 · Cited by 688 · cited 1×
“FDA approval for VNS was received in 2005 as an adjunct therapy for treatment resistant MDD, based on a series of clinical trials (Rush et al. 2000).”
BackgroundSackeim, H. A., Haskett, R. F., Mulsant, B. H., Thase, M. E., Mann, J. J., Pettinati, H. M., Greenberg, R. M., Crowe, R. R., Cooper, T. B., & Prudic, J. (2001) · JAMA · doi:10.1001/jama.285.10.1299 · Cited by 686 · cited 3×
“…coexisting substance abuse • Concurrent coexisting anxiety disorders • Family history of major depressive disorder in fi rst degree relatives • Onset prior to age 30 the recurrence rate was lower for the combination of lithium and nortriptyline vs. nortriptyline alone (Sackeim et al. 2001).”
BackgroundResultInfluentialAkiskal, H. S. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950140032004 · Cited by 679 · cited 2×
“Early age at onset of MDD, high number of episodes early in life, greater acuteness, pleomorphic psychopathology, and high rates of substance abuse have been identifi ed as clinical predictors of the switch to (hypo)mania (Akiskal et al. 1995; Valenti et al. 2012; Pacchiarotti et al. 2013).”
BackgroundInfluentialReynolds III, C. F., Frank, E., Perel, J. M., Imber, S. D., Cornes, C., Miller, M. D., Mazumdar, S., Houck, P. R., Dew, M. A., Stack, J. A., et al. (1999) · JAMA · doi:10.1001/jama.281.1.39 · Cited by 659 · cited 2×
“The effi cacy and safety of nortriptyline in preventing recurrence of major depressive episodes in patients older than 59 were well determined in a 3-year placebo-controlled maintenance study of nortriptyline combined with psychotherapy and nortriptyline monotherapy (Reynolds et al. 1999a).”
BackgroundResultBauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632 · cited 5×
“If the patient does not improve with treatment optimization, another round of adequate acute phase treatment should be initiated followed by continuation treatment (see Part 1 of these guidelines, Bauer et al. 2013).”
BackgroundMethodResultInfluentialSelf-citationBerlim, M. T., van den Eynde, F., Tovar-Perdomo, S., & Daskalakis, Z. J. (2014) · Psychological Medicine · doi:10.1017/s0033291713000512 · Cited by 620 · cited 1×
“The vast majority of the trials conducted on the technique have evaluated the effi cacy of high-frequency rTMS applied to the left dorsolateral prefrontal cortex (Berlim et al. 2014).”
BackgroundAntidepressant-induced mania and cycle acceleration: a controversy revisited
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.8.1130 · Cited by 608 · cited 1×
“Antidepressants, particularly tricyclics, may precipitate mania in some patients with a formal diagnosis of unipolar depression (Altshuler et al. 1995).”
Background(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.12.1 · Cited by 583
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574 · cited 1×
“Data from a RCT showed that discontinuation symptoms are more common with a shorter acting SSRI, such as paroxetine, than with the longer acting agent, such as fl uoxetine (Rosenbaum et al. 1998; Tint et al. 2008).”
BackgroundPrien, R. F. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790220086014 · Cited by 565 · cited 1×
“…provided longitudinal assessments of the side effects of lithium treatment (Schou 1997). start of the maintenance phase was 137 mg, range 75 – 150 mg/day) than lithium (the mean serum lithium level at the start of the maintenance phase was 0.66 mmol/l, range 0.43 – 1.05 mmol/l) (Prien et al. 1984).”
BackgroundInfluentialRapid effects of deep brain stimulation for treatment-resistant major depression
Schlaepfer, T. E., Bewernick, B. H., Kayser, S., Mädler, B., & Coenen, V. A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.01.034 · Cited by 563 · cited 1×
“Preliminary fi ndings show promising results that DBS of certain brain regions may signifi cantly reduce symptoms in treatment-resistant MDD (Schlaepfer et al. 2013).”
BackgroundNelson, J. C., & Papakostas, G. I. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09030312 · Cited by 552 · cited 1×
“Several RCTs have proven their effi cacy in acute treatment studies (Nelson and Papakostas 2009).”
Vittengl, J. R., Clark, L. A., Dunn, T. W., & Jarrett, R. B. (2007) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.75.3.475 · Cited by 551 · cited 1×
“…evidence to support the effi cacy of CBT in the maintenance treatment of major depression, either alone or in combination with antidepressants (Vittengl et al. 2007), with the effect size varying dependent on many variables, such as the control condition (Lynch et al. 2010; Stangier et al.…”
BackgroundLithium toxicity profi le: a systematic review and meta-analysis
McKnight, R. F., Budge, K., Ba, S., Goodwin, G. M., Geddes, J. R., & Adida, M. (2012) · Cited by 544
Kennedy, S. H., Lam, R. W., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.043 · Cited by 525 · cited 1×
“…force recommendations for the management of patients with mood disorders as well as the clinical guidelines for the management of MDDs in adults (Kennedy et al. 2009a, 2009b; Lam et al. 2009; Parikh et al. 2009; Patten et al. 2009; Ravindran et al. 2009; Beaulieu et al. 2012; Bond et al. 2012;…”
BackgroundInterpersonal Psychotherapy for Depression: A Meta-Analysis
Cuijpers, P., Geraedts, A. S., van Oppen, P., Andersson, G., Markowitz, J. C., & van Straten, A. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10101411 · Cited by 511 · cited 3×
“In this study of highly recurrent unipolar depression, all patients enrolled in the 3-year study, had remitted on the combination of imipramine and IPT, and all had remained well for 4 months of continuation therapy prior to randomization.”
BackgroundMaintenance Treatment of Major Depression in Old Age
Reynolds, C. F., Dew, M. A., Pollock, B. G., Mulsant, B. H., Frank, E., Miller, M. D., Houck, P. R., Mazumdar, S., Butters, M. A., Stack, J. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052619 · Cited by 476 · cited 1×
“…implanted The SSRIs were also studied as alternatives to nortriptyline in the maintenance treatment of recurrent depression in older adults (Reynolds et al. 2001, 2006; Klysner et al. 2002; Gorwood et al. 2007) and showed superiority in preventing recurrence in comparison to placebo (for…”
BackgroundThe Course of Depression in Adult Outpatients: Results From the Medical Outcomes Study
Wells, K. B. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820100032007 · Cited by 475 · cited 1×
“Individuals suffering from either dysthymia alone or “ double depression ” have signifi cantly greater impairment in functioning than those with present either major depression alone, depressive symptoms, or past episodes of major depression (Wells et al. 1992).”
BackgroundKellner, C. H., Knapp, R. G., Petrides, G., Rummans, T. A., Husain, M. M., Rasmussen, K., Mueller, M., Bernstein, H. J., O’Connor, K., Smith, G., et al. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.12.1337 · Cited by 471 · cited 1×
“The consideration of the patient ’ s course of illness and treat- ence), monitor pharmacotherapy for safety and to detect breakthrough symptoms early (Rush 1999; Dodd et al. 2011).”
BackgroundThe Clinical Course of Unipolar Major Depressive Disorders
Judd, L. L. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830230015002 · Cited by 460 · cited 2×
“Major depressive disorder, in its classic form, presents as a recurrent disorder (Angst 1986; Kiloh et al. 1988; Judd 1997; Anderson et al. 2008).”
BackgroundSystematic Review and Guide to Selection of Selective Serotonin Reuptake Inhibitors
Edwards, J. G., & Anderson, I. (1999) · Drugs · doi:10.2165/00003495-199957040-00005 · Cited by 458 · cited 1×
“…described with all classes of antidepressants, including TCAs (particularly those with anticholinergic and serotonergic potency), irreversible MAO inhibitors, SSRIs and venlafaxine (Lejoyeux and Ades 1997; Edwards and Anderson 1999), but not with agomelatine (Goodwin et al. 2009) or vortioxetine.”
BackgroundJudd, L. L., Paulus, M. J., Schettler, P. J., Akiskal, H. S., Endicott, J., Leon, A. C., Maser, J. D., Mueller, T., Solomon, D. A., & Keller, M. B. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.9.1501 · Cited by 458 · cited 1×
“Full recovery from MDD is associated with signifi cant delays in treatment emergent episode and a more benign course of illness (Judd and Akiskal 2000; Judd et al. 2000).”
BackgroundLam, R. W., Kennedy, S. H., Grigoriadis, S., McIntyre, R. S., Milev, R., Ramasubbu, R., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.041 · Cited by 431 · cited 3×
“After discontinuation is complete monitoring should continue during the next couple of months (e.g., particularly for the next 6 months, which appear to be a period of high risk for recurrence to identify those in whom a relapse/recurrence is likely) (Lam et al. 2009).”
BackgroundInfluentialSegal, Z. V., Bieling, P., Young, T., MacQueen, G., Cooke, R., Martin, L., Bloch, R., & Levitan, R. D. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.168 · Cited by 429 · cited 1×
“(MBCT) (Segal et al. 2010; Piet and Hougaard 2011) and interpersonal psychotherapy (IPT) (Cuijpers et al. 2011) in this indication.”
BackgroundGrunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & on behalf of the WFSBP Task Force on Treatment Guidelines for Bipolar Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.770551 · Cited by 421 · cited 1×
“They do not address depression occurring in bipolar affective disorders (which are covered by separate WFSBP guidelines) (Grunze et al. 2010, 2013).”
BackgroundSelf-citationGrunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & WFSBP Task Force On Treatment Guidelines For Bipolar Disorders (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622970903555881 · Cited by 399 · cited 1×
“They do not address depression occurring in bipolar affective disorders (which are covered by separate WFSBP guidelines) (Grunze et al. 2010, 2013).”
BackgroundSelf-citationTwo-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes
Nahas, Z., Marangell, L. B., Husain, M. M., Rush, A. J., Sackeim, H. A., Lisanby, S. H., Martinez, J. M., & George, M. S. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0902 · Cited by 390 · cited 1×
“Although response rates with VNS have been modest in the acute phase of treatment (Daban et al. 2008), open label extension phases suggest an increased effect over time (Nahas et al. 2005).”
BackgroundFive-Year Outcome for Maintenance Therapies in Recurrent Depression
Kupfer, D. J. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820100013002 · Cited by 370
Gaynes, B. N., Lloyd, S. W., Lux, L., Gartlehner, G., Hansen, R. A., Brode, S., Jonas, D. E., Evans, T. S., Viswanathan, M., & Lohr, K. N. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13r08815 · Cited by 347 · cited 1×
“TMS is one of the few fundamentally new treatments introduced into psychiatric practice for a considerable number of years (Gaynes et al. 2014; Lepping et al. 2014).”
BackgroundGrunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., WFSBP Task Force on Treatment Guide, Grunze, H., Vieta, E., et al. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970902823202 · Cited by 346 · cited 3×
“…the diagnosis should be revisited, and discontinuation of the antidepressant and concomitant treatment of the manic episode is essential (for more information on the treatment of (hypo)mania, see WFSBP Guidelines for the Treatment of Bipolar Disorder) (Grunze et al. 2009). in the chest region).”
BackgroundMethodSelf-citationBauer, M., Whybrow, P. C., Angst, J., Versiani, M., Möller, H.-J., & WFSBP Task Force on Treatment Guide (2002) · The World Journal of Biological Psychiatry · doi:10.3109/15622970209150599 · Cited by 346 · cited 2×
“The data used for the original development of these guidelines (Bauer et al. 2002b) have been extracted from the following sources: Agency for Health Care Policy and Research (AHCPR) Depression Guidelines Panel (1993); AHCPR Evidence Report on Treatment of Depression: Newer Pharmacotherapies…”
BackgroundMethodSelf-citationGoodwin, G. M., Emsley, R., Rembry, S., Rouillon, F., & the Agomelatine Study Group (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04548 · Cited by 340 · cited 1×
“…described with all classes of antidepressants, including TCAs (particularly those with anticholinergic and serotonergic potency), irreversible MAO inhibitors, SSRIs and venlafaxine (Lejoyeux and Ades 1997; Edwards and Anderson 1999), but not with agomelatine (Goodwin et al. 2009) or vortioxetine.”
BackgroundClinically Significant Pharmacokinetic Drug Interactions with Carbamazepine: An Update
Spina, E., Pisani, F., & Perucca, E. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199631030-00004 · Cited by 331 · cited 2×
“Induction of CYP3A4 by carbamazepine will also accelerate phase I reactions of drugs which are placebo-controlled 2-year study comparing the effi - cacy of mirtazapine with that of amitriptyline found that the time to relapse/recurrence was signifi cantly longer in the mirtazapine group (CE B, RG 3) (Montgomery et al.…”
MethodMohr, D. C., Ho, J., Duffecy, J., Reifler, D., Sokol, L., Burns, M. N., Jin, L., & Siddique, J. (2012) · JAMA · doi:10.1001/jama.2012.5588 · Cited by 330 · cited 1×
“Regarding the mode of delivery, face to face CBT is more effective than telephone-administered CBT at follow-up (Mohr et al. 2012).”
BackgroundLynch, D., Laws, K. R., & McKenna, P. J. (2010) · Psychological Medicine · doi:10.1017/s003329170900590x · Cited by 317 · cited 1×
“…evidence to support the effi cacy of CBT in the maintenance treatment of major depression, either alone or in combination with antidepressants (Vittengl et al. 2007), with the effect size varying dependent on many variables, such as the control condition (Lynch et al. 2010; Stangier et al. 2013).”
BackgroundAngst, J., Sellaro, R., Stassen, H. H., & Gamma, A. (2005) · Journal of Affective Disorders · doi:10.1016/s0165-0327(03)00195-2 · Cited by 311 · cited 1×
“…unipolar depression to bipolar disorder has been described in approximately 10 – 20% of patients (Akiskal et al. 1995; Angst et al. 1978; Solomon et al. 1997), with a conversion rate between 1.5 and 2.0% of unipolar patients per year (Angst et al. 2005; Baldessarini et al. 2013; Dudek et al. 2013).”
BackgroundInfluentialSelf-citationLam, R. W., Chan, P., Wilkins-Ho, M., & Yatham, L. N. (2008) · The Canadian Journal of Psychiatry · doi:10.1177/070674370805300909 · Cited by 297
A Randomized Trial of Relapse Prevention of Depression in Primary Care
Katon, W., Rutter, C., Ludman, E. J., Von Korff, M., Lin, E., Simon, G., Bush, T., Walker, E., & Unützer, J. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.3.241 · Cited by 295 · cited 1×
“…a low intensity intervention including enhanced patient education, visits with a depression specialist, telephone calls, symptom monitoring) for depressed patients in primary care may improve antidepressant adherence and depressive symptoms compared with usual primary care (Katon et al. 2001).”
BackgroundShould depression be managed as a chronic disease?
Andrews, G. (2001) · BMJ · doi:10.1136/bmj.322.7283.419 · Cited by 260 · cited 1×
“Fifty to 85% of the patients who have a major depressive episode will have another episode (Mueller et al. 1999; American Psychiatric Association 2000; Andrews 2001).”
BackgroundAustralian and New Zealand Clinical Practice Guidelines for the Treatment of Depression
Royal Australian And New Zealand College Of Psychiatrists Clinical Practice Guidelines Team For Depression (2004) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2004.01377.x · Cited by 257
(1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.1.24 · Cited by 255 · cited 1×
“It is now well established that about onethird of patients suffering from severe major depression will have a chronic course marked by at least 2 years of illness (Keller et al. 1986; Scott 1988; American Psychiatric Association 2000; Judd and Akiskal 2000).”
BackgroundPeretti, S., Judge, R., & Hindmarch, I. (2000) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2000.tb10944.x · Cited by 236 · cited 1×
“…older tricyclics and tetracyclics (for details about side effects of antidepressants see Part 1 of these guidelines, Agency for Health Care Policy and Research 1993; American Psychiatric Association 2000; Bauer et al. 2002a; Peretti et al. 2000), apart from sexual dysfunction (Taylor et al. 2013).”
BackgroundThe Long-Term Outcome of Depressive Illness
Kiloh, L. G., Andrews, G., & Neilson, M. (1988) · British Journal of Psychiatry · doi:10.1192/bjp.153.6.752 · Cited by 234 · cited 1×
“Major depressive disorder, in its classic form, presents as a recurrent disorder (Angst 1986; Kiloh et al. 1988; Judd 1997; Anderson et al. 2008).”
BackgroundLithium for maintenance treatment of mood disorders
Burgess, S. S., Geddes, J., Hawton, K. K., Taylor, M. J., Townsend, E., Jamison, K., & Goodwin, G. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003013 · Cited by 232 · cited 1×
“Two meta-analysis found evidence that lithium is more effective than placebo in preventing recurrence of unipolar depressive illness (Souza and Goodwin 1991; Burgess et al. 2001), but only in one the results were statistically signifi cant (Souza and Goodwin 1991).”
BackgroundStrategies for managing sexual dysfunction induced by antidepressant medication
Taylor, M. J., Rudkin, L., Bullemor-Day, P., Lubin, J., Chukwujekwu, C., & Hawton, K. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003382.pub3 · Cited by 225
Kennedy, S. H., Milev, R., Giacobbe, P., Ramasubbu, R., Lam, R. W., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.039 · Cited by 222 · cited 1×
“…force recommendations for the management of patients with mood disorders as well as the clinical guidelines for the management of MDDs in adults (Kennedy et al. 2009a, 2009b; Lam et al. 2009; Parikh et al. 2009; Patten et al. 2009; Ravindran et al. 2009; Beaulieu et al. 2012; Bond et al. 2012;…”
BackgroundAntidepressant Discontinuation Syndromes: Clinical Relevance, Prevention and Management
Haddad, P. M. (2001) · Drug Safety · doi:10.2165/00002018-200124030-00003 · Cited by 214 · cited 2×
“Typically these symptoms subside with the reinstatement of the original drug (Haddad 2001).”
BackgroundKane, J. M. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290090053011 · Cited by 212 · cited 1×
“In one relatively small randomized, placebo-controlled 2-year maintenance study lithium (serum level 0.8 – 1.2 mmol/l) was superior to imipramine (100 – 150 mg/day); the combination of lithium and imipramine was not superior to lithium alone (Kane et al. 1982).”
BackgroundInfluentialLithium Treatment Reduces Suicide Risk in Recurrent Major Depressive Disorder
Guzzetta, F., Tondo, L., Centorrino, F., & Baldessarini, R. J. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0304 · Cited by 208 · cited 1×
“In a meta-analysis in unipolar depression, lithium was found to signifi cantly prevent suicide attempts and suicides (Guzzetta et al. 2007).”
BackgroundA different depression: clinical distinctions between bipolar and unipolar depression
Bowden, C. L. (2005) · Journal of Affective Disorders · doi:10.1016/s0165-0327(03)00194-0 · Cited by 207 · cited 1×
“In addition family history of bipolar disorder might be a helpful predictor for a switch to bipolar disorder among patients with recurrent unipolar depression (Bowden 2005).”
BackgroundRamasubbu, R., Taylor, V. H., Samaan, Z., Sockalingham, S., Li, M., Patten, S., Rodin, G., Schaffer, A., Beaulieu, S., & McIntyre, R. S. (2012) · Annals of Clinical Psychiatry · doi:10.1177/104012371202400110 · Cited by 206 · cited 1×
“…et al. 2009; Parikh et al. 2009; Patten et al. 2009; Ravindran et al. 2009; Beaulieu et al. 2012; Bond et al. 2012; McIntyre et al. 2012a, 2012b; Ramasubbu et al. 2012a, 2012b; Rosenbluth et al. 2012; Schaffer et al. 2012), the British Association for Psychopharmacology guidelines for treating…”
BackgroundEffect of Prophylactic Treatment on Suicide Risk in Patients with Major Affective Disorders
Thies-Flechtner, K., Müller-Oerlinghausen, B., Seibert, W., Walther, A., & Greil, W. (1996) · Pharmacopsychiatry · doi:10.1055/s-2007-979553 · Cited by 205 · cited 1×
“A randomized 2.5-year maintenance treatment study in patients with major affective disorder showed signifi cantly less suicides and suicide attempts in the lithium group compared with the carbamazepine group (Thies-Flechtner et al. 1996).”
ResultInfluentialAmerican Journal of Psychiatry celebrates 150th anniversary
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.6.1 · Cited by 202
Recovery From Major Depression: A 10-Year Prospective Follow-up Across Multiple Episodes
Solomon, D. A. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830230033005 · Cited by 199
Depressive disorders and suicide: Epidemiology, risk factors, and burden
Miret, M., Ayuso-Mateos, J. L., Sanchez-Moreno, J., & Vieta, E. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.01.008 · Cited by 199 · cited 1×
“Patients with an early onset (between age 15 and 25) and a high number of recurrences early in life are at risk to develop (hypo-)manic episodes (and convert to bipolar disorder) (Angst et al. 2013; Miret et al. 2013).”
BackgroundA Controlled Family History Study of Childhood-Onset Depressive Disorder
Kovacs, M. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830190033004 · Cited by 192 · cited 1×
“…of MDD are: prior history of multiple episodes, early age at onset, persistence of dysthymic symptoms after recovery from an episode, presence of an additional, non-mood psychiatric diagnosis, and presence of a chronic physical disorder (Kovacs et al. 1997; American Psychiatric Association 2000).”
BackgroundParoxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression
Montgomery, S. A., & Dunbar, G. (1993) · International Clinical Psychopharmacology · doi:10.1097/00004850-199300830-00009 · Cited by 188 · cited 1×
“…A, RG 1), fl uoxetine (Gilaberte et al. 2001; Keller et al. 2007)) (CE A, RG 2), fl uvoxamine (Terra and Montgomery 1998) (CE A, RG 2), paroxetine (Montgomery and Dunbar 1993) (CE A, RG 1) and sertraline (Lepine et al. 2004)] (CE A, RG 1) and SNRIs (venlafaxine (Montgomery et al. 2004; Kocsis et…”
BackgroundFluoxetine versus placebo in preventing relapse of major depression in children and adolescents
Emslie, G. J., Kennard, B. D., Mayes, T. L., Nightingale-Teresi, J., Carmody, T., Hughes, C. W., Rush, A. J., Tao, R., & Rintelmann, J. W. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07091453 · Cited by 188 · cited 1×
“In recent years several studies have been performed to examine effi - cacy of antidepressants and their potential to prevent new depressive episodes after remission or response in children and adolescents (Brent et al. 2008; Cheung et al. 2008; Emslie et al. 2008).”
BackgroundThe Course of Affective Disorders
Angst, J. (1986) · Psychopathology · doi:10.1159/000285131 · Cited by 186
Self-citationLithium: a review of its metabolic adverse effects
Livingstone, C., & Rampes, H. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881105057515 · Cited by 184 · cited 1×
“…function (e.g., blood calcium and, if elevated, also parathyroid hormone) and renal function (creatinine, eGFR) (e.g., once or twice a year) is recommended (American Psychiatric Association 1994; Berger et al. 2013; Bschor 2014; Livingstone and Rampes 2006; Schou 1997; Severus and Bauer 2013).”
BackgroundParikh, S. V., Segal, Z. V., Grigoriadis, S., Ravindran, A. V., Kennedy, S. H., Lam, R. W., & Patten, S. B. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.042 · Cited by 183 · cited 1×
“…patients with mood disorders as well as the clinical guidelines for the management of MDDs in adults (Kennedy et al. 2009a, 2009b; Lam et al. 2009; Parikh et al. 2009; Patten et al. 2009; Ravindran et al. 2009; Beaulieu et al. 2012; Bond et al. 2012; McIntyre et al. 2012a, 2012b; Ramasubbu et al.…”
BackgroundRenal failure occurs in chronic lithium treatment but is uncommon
Bendz, H., Schön, S., Attman, P.-O., & Aurell, M. (2010) · Kidney International · doi:10.1038/ki.2009.433 · Cited by 183 · cited 1×
“However, in patients treated with 15 or more years of lithium therapy, affection of both glomerular and tubular function seems to be more common (Bendz et al. 2010).”
BackgroundJudd, L., & Akiskal, H. (2000) · Pharmacopsychiatry · doi:10.1055/s-2000-7967 · Cited by 182 · cited 3×
“It is now well established that about onethird of patients suffering from severe major depression will have a chronic course marked by at least 2 years of illness (Keller et al. 1986; Scott 1988; American Psychiatric Association 2000; Judd and Akiskal 2000).”
BackgroundBauer, M., Bschor, T., Kunz, D., Berghöfer, A., Ströhle, A., & Müller-Oerlinghausen, B. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.9.1429 · Cited by 176 · cited 1×
“The use of lithium as maintenance therapy for recurrent unipolar depression is well established (CE A, RG 2) (Schou 1997; Davis et al. 1999; Bauer et al. 2000, 2014; Coppen 2000; Paykel 2001; Bschor et al. 2002; Davis 2006).”
BackgroundSelf-citationStangier, U., Hilling, C., Heidenreich, T., Risch, A. K., Barocka, A., Schlösser, R., Kronfeld, K., Ruckes, C., Berger, H., Röschke, J., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12060734 · Cited by 174
Baldessarini, R. J., Faedda, G. L., Offidani, E., Vázquez, G. H., Marangoni, C., Serra, G., & Tondo, L. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.10.033 · Cited by 169 · cited 1×
“…unipolar depression to bipolar disorder has been described in approximately 10 – 20% of patients (Akiskal et al. 1995; Angst et al. 1978; Solomon et al. 1997), with a conversion rate between 1.5 and 2.0% of unipolar patients per year (Angst et al. 2005; Baldessarini et al. 2013; Dudek et al. 2013).”
BackgroundInfluentialForty Years of Lithium Treatment
Schou, M. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830130013002 · Cited by 165
Aaronson, S. T., Carpenter, L. L., Conway, C. R., Reimherr, F. W., Lisanby, S. H., Schwartz, T. L., Moreno, F. A., Dunner, D. L., Lesem, M. D., Thompson, P. M., et al. (2013) · Brain Stimulation · doi:10.1016/j.brs.2012.09.013 · Cited by 163 · cited 1×
“…double-blind trial that used VNS in treatment resistant depression, medium and high VNS stimulation dose was not more effective than low dose (pseudo-placebo) in the acute treatment, but in posthoc analyses they were superior to low dose VNS in long-term treatment (Aaronson et al. 2013).”
BackgroundDaban, C., Martinez-Aran, A., Cruz, N., & Vieta, E. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.02.012 · Cited by 163 · cited 1×
“Although response rates with VNS have been modest in the acute phase of treatment (Daban et al. 2008), open label extension phases suggest an increased effect over time (Nahas et al. 2005).”
BackgroundBauer, M., Whybrow, P. C., Angst, J., Versiani, M., Möller, H.-J., & WFSBP Task Force on Treatment Guide (2002) · The World Journal of Biological Psychiatry · doi:10.3109/15622970209150605 · Cited by 160 · cited 2×
“The data used for the original development of these guidelines (Bauer et al. 2002b) have been extracted from the following sources: Agency for Health Care Policy and Research (AHCPR) Depression Guidelines Panel (1993); AHCPR Evidence Report on Treatment of Depression: Newer Pharmacotherapies…”
BackgroundMethodSelf-citationScott, J. (1988) · British Journal of Psychiatry · doi:10.1192/bjp.153.3.287 · Cited by 160
Antidepressant discontinuation syndromes
Haddad, P. M., Anderson, I., & Rosenbaum, J. (2004) · Adverse Syndromes and Psychiatric Drugs · doi:10.1093/med/9780198527480.003.0010 · Cited by 160
Müller‐Oerlinghausen, B., Ahrens, B., Grof, E., Grof, P., Lenz, G., Schou, M., Simhandl, C., Thau, K., Volk, J., Wolf, R., et al. (1992) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1992.tb03255.x · Cited by 159 · cited 1×
“Over the past decade, evidence has accumulated from retrospective and prospective studies that longterm lithium prophylaxis may reduce suicide risk and even normalize the high mortality rate (CE B, RG 3) (Coppen et al. 1990; M ü ller-Oerlinghausen et al. 1992, 1994; Tondo et al. 1997; Schou 2000).”
Background(1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810090025004 · Cited by 157 · cited 2×
“Other controlled studies have also supported the effi cacy of nortriptyline in preventing recurrence of major depressive episodes in older adults (CE A, RG 2) (Georgotas et al. 1989; Reynolds et al. 1999b).”
MethodResultLauterbach, E., Felber, W., Müller‐Oerlinghausen, B., Ahrens, B., Bronisch, T., Meyer, T., Kilb, B., Lewitzka, U., Hawellek, B., Quante, A., et al. (2008) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01266.x · Cited by 154 · cited 1×
“In the only prospective randomized placebo-controlled study (52 weeks) in patients with a high suicide risk, 3.6% of placebotreated subjects committed suicide, but none of the lithium-treated participants ( N 167, P 0.049) (Lauterbach et al. 2008).”
BackgroundInfluentialMood disorders pharmacologic prevention of recurrences
Kupfer, D. J., Berger, P. A., Janeway, J., Endicott, J., Gergen, J. A., Guze, S. A., Hollister, L. E., Keller, M., & LASKA, E. M. (1985) · American Journal of Psychiatry · Cited by 154
(1985) · American Journal of Psychiatry · doi:10.1176/ajp.142.4.469 · Cited by 152
Continuation and Maintenance Electroconvulsive Therapy for Mood Disorders: Review of the Literature
Petrides, G., Tobias, K. G., Kellner, C. H., & Rudorfer, M. V. (2011) · Neuropsychobiology · doi:10.1159/000328943 · Cited by 151 · cited 3×
“A recent review listed six prospective naturalistic studies (Wijkstra et al. 2000; Datto et al. 2001; Swoboda et al. 2001; Rami-Gonzalez et al. 2003; Vothknecht et al. 2003; Rami et al. 2004; Odeberg et al. 2008) and two RCTs (Kellner et al. 2006; Navarro et al. 2008) examining continuation- (C-ECT) or maintenanceECT…”
BackgroundContinuation and maintenance treatments for depression in older people
Wilkinson, P., & Izmeth, Z. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006727.pub3 · Cited by 151
The Advantage of Early Treatment Intervention in Recurrent Depression
(1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810090013002 · Cited by 150 · cited 1×
“Early intervention can shorten the length of the episode (Kupfer et al. 1989).”
BackgroundAntidepressant discontinuation: a review of the literature.
Lejoyeux, M., & Adès, J. (1997) · PubMed · Cited by 148
Patten, S. B., Kennedy, S. H., Lam, R. W., O'Donovan, C., Filteau, M. J., Parikh, S. V., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.044 · Cited by 148 · cited 1×
“…disorders as well as the clinical guidelines for the management of MDDs in adults (Kennedy et al. 2009a, 2009b; Lam et al. 2009; Parikh et al. 2009; Patten et al. 2009; Ravindran et al. 2009; Beaulieu et al. 2012; Bond et al. 2012; McIntyre et al. 2012a, 2012b; Ramasubbu et al. 2012a, 2012b;…”
BackgroundLithium Treatment and Prophylaxis in Unipolar Depression: A Meta-analysis
Souza, F. G. M., & Goodwin, G. M. (1991) · British Journal of Psychiatry · doi:10.1192/bjp.158.5.666 · Cited by 144 · cited 2×
“Two meta-analysis found evidence that lithium is more effective than placebo in preventing recurrence of unipolar depressive illness (Souza and Goodwin 1991; Burgess et al. 2001), but only in one the results were statistically signifi cant (Souza and Goodwin 1991).”
BackgroundEffect of Lithium Maintenance on. Suicidal Behavior in Major Mood Disordersa
TONDO, L., JAMISON, K. R., & BALDESSARINI, R. J. (1997) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1997.tb52369.x · Cited by 142 · cited 1×
“Over the past decade, evidence has accumulated from retrospective and prospective studies that longterm lithium prophylaxis may reduce suicide risk and even normalize the high mortality rate (CE B, RG 3) (Coppen et al. 1990; M ü ller-Oerlinghausen et al. 1992, 1994; Tondo et al. 1997; Schou 2000).”
BackgroundPlacidi, G. F., Lenzi, A., Lazzerini, F., Cassano, G., & Akiskal, H. S. (1986) · PubMed · Cited by 142
Role of Lithium Augmentation in the Management of Major Depressive Disorder
Bauer, M., Adli, M., Ricken, R., Severus, E., & Pilhatsch, M. (2014) · CNS Drugs · doi:10.1007/s40263-014-0152-8 · Cited by 139 · cited 1×
“The use of lithium as maintenance therapy for recurrent unipolar depression is well established (CE A, RG 2) (Schou 1997; Davis et al. 1999; Bauer et al. 2000, 2014; Coppen 2000; Paykel 2001; Bschor et al. 2002; Davis 2006).”
BackgroundSelf-citationBrakemeier, E., Merkl, A., Wilbertz, G., Quante, A., Regen, F., Bührsch, N., van Hall, F., Kischkel, E., Danker‐Hopfe, H., Anghelescu, I. G., et al. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.11.030 · Cited by 134 · cited 17×
“In a placebo-controlled RCT investigating different treatment strategies after open-label ECT treatment, used in addition to carbamazepine if they are metabolized via CYP3A4 (Spina et al. 1996).”
BackgroundInfluentialWhat is the optimal serum lithium level in the long‐term treatment of bipolar disorder – a review?
Severus, W., Kleindienst, N., Seemüller, F., Frangou, S., Möller, H., & Greil, W. (2008) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00475.x · Cited by 134 · cited 1×
“Serum lithium levels of 0.6 – 0.8 mmol/l (mEq/l) drawn 12 h after last lithium intake are usually recommended for maintenance treatment of mood disorders (Schou 1989; Severus et al. 2008; Malhi et al. 2011; Nolen and Weisler 2013).”
BackgroundInfluentialSelf-citationBond, D. J., Hadjipavlou, G., Lam, R. W., McIntyre, R. S., Beaulieu, S., Schaffer, A., & Weiss, M. (2012) · Annals of Clinical Psychiatry · doi:10.1177/104012371202400104 · Cited by 133 · cited 1×
“…MDDs in adults (Kennedy et al. 2009a, 2009b; Lam et al. 2009; Parikh et al. 2009; Patten et al. 2009; Ravindran et al. 2009; Beaulieu et al. 2012; Bond et al. 2012; McIntyre et al. 2012a, 2012b; Ramasubbu et al. 2012a, 2012b; Rosenbluth et al. 2012; Schaffer et al. 2012), the British Association…”
BackgroundBoulenger, J.-P., Loft, H., & Florea, I. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112441866 · Cited by 127 · cited 1×
“Some patients fi nd that a single daily dose facilitates long-term treatment adherence and A, RG 2) and duloxetine (Perahia et al. 2009; Kelin et al. 2010) (CE A, RG 2) and vortioxetine (Boulenger et al. 2012) (CE B, RG 3) are effective in preventing recurrence of depression.”
BackgroundNavarro, V., Gastó, C., Torres, X., Masana, G., Penadés, R., Guarch, J., Vázquez, M., Serra, M., Pujol, N., Pintor, L., et al. (2008) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e318170a6fa · Cited by 125 · cited 1×
“…studies (Wijkstra et al. 2000; Datto et al. 2001; Swoboda et al. 2001; Rami-Gonzalez et al. 2003; Vothknecht et al. 2003; Rami et al. 2004; Odeberg et al. 2008) and two RCTs (Kellner et al. 2006; Navarro et al. 2008) examining continuation- (C-ECT) or maintenanceECT (M-ECT) (Petrides et al. 2011).”
BackgroundMontgomery, S. A., Reimitz, P. E., & Zivkov, M. (1998) · International Clinical Psychopharmacology · doi:10.1097/00004850-199803000-00002 · Cited by 122 · cited 1×
“…will also accelerate phase I reactions of drugs which are placebo-controlled 2-year study comparing the effi - cacy of mirtazapine with that of amitriptyline found that the time to relapse/recurrence was signifi cantly longer in the mirtazapine group (CE B, RG 3) (Montgomery et al. 1998).”
ResultEscitalopram continuation treatment prevents relapse of depressive episodes
Rapaport, M. H., Bose, A., & Zheng, H. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0107 · Cited by 121 · cited 1×
“…2000; Paykel 2001; van den Broek et al. 2006), SSRIs (citalopram (Hochstrasser et al. 2001; Klysner et al. 2002)) (CE A, RG 1), escitalopram (Rapaport et al. 2004; Kornstein et al. 2006)) (CE A, RG 1), fl uoxetine (Gilaberte et al. 2001; Keller et al. 2007)) (CE A, RG 2), fl uvoxamine…”
BackgroundMood stabilizers in the prevention of recurrent affective disorders: a meta‐analysis
Davis, J. M., Janicak, P. G., & Hogan, D. M. (1999) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1999.tb10890.x · Cited by 120 · cited 2×
“The use of lithium as maintenance therapy for recurrent unipolar depression is well established (CE A, RG 2) (Schou 1997; Davis et al. 1999; Bauer et al. 2000, 2014; Coppen 2000; Paykel 2001; Bschor et al. 2002; Davis 2006).”
BackgroundLong-Term Maintenance Therapy for Major Depressive Disorder With rTMS
O'Reardon, J. P., Blumner, K. H., Peshek, A. D., Pradilla, R. R., & Pimiento, P. C. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1205 · Cited by 118 · cited 1×
“Maintenance rTMS for depression has only been explored very rarely (CE C1, RG4) (O ’ Reardon et al. 2005).”
BackgroundWilliams, L. J., Henry, M. J., Berk, M., Dodd, S., Jacka, F. N., Kotowicz, M. A., Nicholson, G. C., & Pasco, J. A. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282f2b3bb · Cited by 117 · cited 1×
“However, there is recent concern about the capacity of SSRI antidepressants to reduce bone mineral density, with long-term implications including increased fracture risk (Schwan and Hallberg 2009; Williams et al. 2008).”
BackgroundIntroduction: treatment of depression in long-term care patients.
Thase, M. E. (1999) · PubMed · Cited by 116
Australian and New Zealand clinical practice guidelines for the treatment of depression
(2004) · Australian & New Zealand Journal of Psychiatry · doi:10.1111/j.1440-1614.2004.01377.x · Cited by 115
Lifestyle management of unipolar depression
Berk, M., Sarris, J., Coulson, C. E., & Jacka, F. N. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12124 · Cited by 111 · cited 1×
“Lastly, attention to lifestyle factors including smoking cessation, diet and exercise is of value (Berk et al. 2013).”
BackgroundRavindran, A. V., Lam, R. W., Filteau, M. J., Lespérance, F., Kennedy, S. H., Parikh, S. V., & Patten, S. B. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.040 · Cited by 108 · cited 1×
“…the clinical guidelines for the management of MDDs in adults (Kennedy et al. 2009a, 2009b; Lam et al. 2009; Parikh et al. 2009; Patten et al. 2009; Ravindran et al. 2009; Beaulieu et al. 2012; Bond et al. 2012; McIntyre et al. 2012a, 2012b; Ramasubbu et al. 2012a, 2012b; Rosenbluth et al. 2012;…”
BackgroundKlysner, R., Bent-Hansen, J., Hansen, H. L., Lunde, M., Pleidrup, E., Poulsen, D. L., Andersen, M., & Petersen, H. E. H. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.181.1.29 · Cited by 106 · cited 2×
“…llerOerlinghausen 1999; American Psychiatric Association 2000; Paykel 2001; van den Broek et al. 2006), SSRIs (citalopram (Hochstrasser et al. 2001; Klysner et al. 2002)) (CE A, RG 1), escitalopram (Rapaport et al. 2004; Kornstein et al. 2006)) (CE A, RG 1), fl uoxetine (Gilaberte et al. 2001;…”
BackgroundTherapeutic options in treatment-resistant depression
Vieta, E., & Colom, F. (2011) · Annals of Medicine · doi:10.3109/07853890.2011.583675 · Cited by 102 · cited 1×
“Atypical antipsychotics have been investigated in unipolar depression as an augmentation strategy (Vieta and Colom 2011).”
Background(2012) · PubMed · Cited by 100
Fitzgerald, P. B., & Daskalakis, Z. J. (2012) · Brain Stimulation · doi:10.1016/j.brs.2011.03.006 · Cited by 97 · cited 1×
“However there are more intensive treatment regimens for maintenance rTMS (Fitzgerald and Daskalakis 2012).”
BackgroundFamily psychoeducation for major depression: randomised controlled trial
Shimazu, K., Shimodera, S., Mino, Y., Nishida, A., Kamimura, N., Sawada, K., Fujita, H., Furukawa, T. A., & Inoue, S. (2011) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.078626 · Cited by 95 · cited 1×
“Furthermore initial data hint at the effectiveness of family psychoeducation (Shimazu et al. 2011).”
BackgroundLithium in the treatment of major depressive disorder
Bschor, T. (2014) · Drugs · doi:10.1007/s40265-014-0220-x · Cited by 94 · cited 1×
“…function (e.g., blood calcium and, if elevated, also parathyroid hormone) and renal function (creatinine, eGFR) (e.g., once or twice a year) is recommended (American Psychiatric Association 1994; Berger et al. 2013; Bschor 2014; Livingstone and Rampes 2006; Schou 1997; Severus and Bauer 2013).”
BackgroundEscitalopram Prevents Relapse in Older Patients With Major Depressive Disorder
Gorwood, P. A. P. M., Weiller, E., Lemming, O. M., & Katona, C. (2007) · American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000240823.94522.4c · Cited by 94 · cited 1×
“…alternatives to nortriptyline in the maintenance treatment of recurrent depression in older adults (Reynolds et al. 2001, 2006; Klysner et al. 2002; Gorwood et al. 2007) and showed superiority in preventing recurrence in comparison to placebo (for paroxetine, escitalopram and citalopram, not for…”
BackgroundMaintenance Electroconvulsive Therapy in Affective and Schizoaffective Disorder
Swoboda, E., Conca, A., König, P., Waanders, R., & Hansen, M. (2001) · Neuropsychobiology · doi:10.1159/000054861 · Cited by 92 · cited 1×
“A recent review listed six prospective naturalistic studies (Wijkstra et al. 2000; Datto et al. 2001; Swoboda et al. 2001; Rami-Gonzalez et al. 2003; Vothknecht et al. 2003; Rami et al. 2004; Odeberg et al. 2008) and two RCTs (Kellner et al. 2006; Navarro et al. 2008) examining continuation-…”
BackgroundThe course of affective disorders
Angst, J., Felder, W., Frey, R., & Stassen, H. H. (1978) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf00344124 · Cited by 89
Self-citationMethodologic issues in maintenance therapy clinical trials
Greenhouse, J. B. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810280029004 · Cited by 89 · cited 1×
“However, in a later reanalysis of the data the same authors concluded that the results of the latter study could be accounted for by alternative explanations that are a consequence of the study design (Greenhouse et al. 1991).”
ResultAngst, J., Gamma, A., Bowden, C. L., Azorin, J., Perugi, G., Vieta, E., & Young, A. H. (2013) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-013-0393-4 · Cited by 88 · cited 1×
“Patients with an early onset (between age 15 and 25) and a high number of recurrences early in life are at risk to develop (hypo-)manic episodes (and convert to bipolar disorder) (Angst et al. 2013; Miret et al. 2013).”
BackgroundSelf-citationLiebowitz, M., Lam, R. W., Lepola, U., Datto, C., Sweitzer, D., & Eriksson, H. (2010) · Depression and Anxiety · doi:10.1002/da.20740 · Cited by 86 · cited 1×
“Recently one RCT demonstrated the superiority of quetiapine in maintenance monotherapy treatment to prevent relapse/recurrence for MDD (CE B, RG 3) (Liebowitz et al. 2010).”
BackgroundRisk Factors for Antidepressant-Related Switch to Mania
Valentí, M., Pacchiarotti, I., Bonnín, C. M., Rosa, A. R., Popovic, D., Nivoli, A. M. A., Goikolea, J. M., Murru, A., Undurraga, J., Colom, F., et al. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07166 · Cited by 86 · cited 1×
“Early age at onset of MDD, high number of episodes early in life, greater acuteness, pleomorphic psychopathology, and high rates of substance abuse have been identifi ed as clinical predictors of the switch to (hypo)mania (Akiskal et al. 1995; Valenti et al. 2012; Pacchiarotti et al. 2013).”
BackgroundHochstrasser, B., Isaksen, P. M., Koponen, H., Lauritzen, L., Mahnert, F. A., Rouillon, F., Wade, A. G., Andersen, M., Pedersen, S. F., De Swart, J. C. G., et al. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.4.304 · Cited by 85 · cited 1×
“…Montgomery 1994; M ü llerOerlinghausen 1999; American Psychiatric Association 2000; Paykel 2001; van den Broek et al. 2006), SSRIs (citalopram (Hochstrasser et al. 2001; Klysner et al. 2002)) (CE A, RG 1), escitalopram (Rapaport et al. 2004; Kornstein et al. 2006)) (CE A, RG 1), fl uoxetine…”
BackgroundGreil, W., Ludwig‐Mayerhofer, W., Erazo, N., Engel, R. R., Czernik, A., Giedke, H., Müller-Oerlinghausen, B., Osterheider, M., Rudolf, G. A. E., Sauer, H., et al. (1996) · Journal of Affective Disorders · doi:10.1016/0165-0327(96)00070-5 · Cited by 84 · cited 1×
“One randomized prospective, open 2.5-year trial comparing lithium (average serum lithium level 0.59 mmol/l) with amitriptyline (average dosage 98 mg/day) found signifi cantly better prophylactic effi cacy for lithium (Greil et al. 1996).”
BackgroundInfluentialLépine, J.-P., Caillard, V., Bisserbe, J.-C., Troy, S., Hotton, J.-M., Boyer, P., & For the PREVERS Investigators (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.836 · Cited by 83 · cited 2×
“…2001; Keller et al. 2007)) (CE A, RG 2), fl uvoxamine (Terra and Montgomery 1998) (CE A, RG 2), paroxetine (Montgomery and Dunbar 1993) (CE A, RG 1) and sertraline (Lepine et al. 2004)] (CE A, RG 1) and SNRIs (venlafaxine (Montgomery et al. 2004; Kocsis et al. 2007)) (CE improvement, if indicated.”
BackgroundLithium prophylaxis: myths and realities
(1989) · American Journal of Psychiatry · doi:10.1176/ajp.146.5.573 · Cited by 83
Major depression in 1998: are we providing optimal therapy?
Angst, J. (1999) · PubMed · Cited by 78
Self-citationDudek, D., Siwek, M., Zielińska, D., Jaeschke, R., & Rybakowski, J. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.06.014 · Cited by 77 · cited 1×
“…unipolar depression to bipolar disorder has been described in approximately 10 – 20% of patients (Akiskal et al. 1995; Angst et al. 1978; Solomon et al. 1997), with a conversion rate between 1.5 and 2.0% of unipolar patients per year (Angst et al. 2005; Baldessarini et al. 2013; Dudek et al. 2013).”
BackgroundInfluentialChronic Depression in the Elderly: Approaches for Prevention
Reynolds, C. F., Alexopoulos, G. S., Katz, I. R., & Lebowitz, B. D. (2001) · Drugs & Aging · doi:10.2165/00002512-200118070-00004 · Cited by 76
Shrivastava, R. K., Cohn, C., Crowder, J., Davidson, J. R. T., Dünner, D. L., Feighner, J. P., Kiev, A., & Patrick, R. (1994) · PubMed · Cited by 76
Wilson, K. C. M., Mottram, P. G., Ashworth, L., & Abou-Saleh, M. T. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.182.6.492 · Cited by 74 · cited 1×
“…the maintenance treatment of recurrent depression in older adults (Reynolds et al. 2001, 2006; Klysner et al. 2002; Gorwood et al. 2007) and showed superiority in preventing recurrence in comparison to placebo (for paroxetine, escitalopram and citalopram, not for sertraline (Wilson et al. 2003)).”
BackgroundMüller‐Oerlinghausen, B., Wolf, T., Ahrens, B., Schou, M., Grof, E., Grof, P., Lenz, G., Simhandl, C., Thau, K., & Wolf, R. (1994) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1994.tb01596.x · Cited by 73 · cited 1×
“Over the past decade, evidence has accumulated from retrospective and prospective studies that longterm lithium prophylaxis may reduce suicide risk and even normalize the high mortality rate (CE B, RG 3) (Coppen et al. 1990; M ü ller-Oerlinghausen et al. 1992, 1994; Tondo et al. 1997; Schou 2000).”
BackgroundNolen, W. A., & Weisler, R. H. (2013) · Bipolar Disorders · doi:10.1111/bdi.12027 · Cited by 73 · cited 1×
“Serum lithium levels of 0.6 – 0.8 mmol/l (mEq/l) drawn 12 h after last lithium intake are usually recommended for maintenance treatment of mood disorders (Schou 1989; Severus et al. 2008; Malhi et al. 2011; Nolen and Weisler 2013).”
BackgroundInfluentialContinuation and maintenance therapy in depression
Paykel, E. S. (2001) · British Medical Bulletin · doi:10.1093/bmb/57.1.145 · Cited by 73 · cited 4×
“The use of lithium as maintenance therapy for recurrent unipolar depression is well established (CE A, RG 2) (Schou 1997; Davis et al. 1999; Bauer et al. 2000, 2014; Coppen 2000; Paykel 2001; Bschor et al. 2002; Davis 2006).”
BackgroundInfluentialRamasubbu, R., Beaulieu, S., Taylor, V. H., Schaffer, A., & McIntyre, R. S. (2012) · Annals of Clinical Psychiatry · doi:10.1177/104012371202400109 · Cited by 69 · cited 1×
“…et al. 2009; Parikh et al. 2009; Patten et al. 2009; Ravindran et al. 2009; Beaulieu et al. 2012; Bond et al. 2012; McIntyre et al. 2012a, 2012b; Ramasubbu et al. 2012a, 2012b; Rosenbluth et al. 2012; Schaffer et al. 2012), the British Association for Psychopharmacology guidelines for treating…”
BackgroundLong-Term Treatment of Depression
Montgomery, S. A. (1994) · British Journal of Psychiatry · doi:10.1192/s0007125000293264 · Cited by 69
Venlafaxine Versus Placebo in the Preventive Treatment of Recurrent Major Depression
Montgomery, S. A., Entsuah, R., Hackett, D., Kunz, N. R., Rudolph, R. L., & Venlafaxine 335 Study Group (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0307 · Cited by 69 · cited 1×
“…2001; Keller et al. 2007)) (CE A, RG 2), fl uvoxamine (Terra and Montgomery 1998) (CE A, RG 2), paroxetine (Montgomery and Dunbar 1993) (CE A, RG 1) and sertraline (Lepine et al. 2004)] (CE A, RG 1) and SNRIs (venlafaxine (Montgomery et al. 2004; Kocsis et al. 2007)) (CE improvement, if indicated.”
Long-Term Safety and Clinical Acceptability of: Venlafaxine and Imipramine in Outpatients
SHRIVASTAVA, R. K., COHN, C., CROWDER, J., DAVIDSON, J., DUNNER, D., FEIGHNER, J., KIEV, A., & PATRICK, R. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199410000-00006 · Cited by 67 · cited 1×
“Similarly, a double-blind 1-year study reported signifi cantly greater improvement in some of the outcome measures in the venlafaxine group compared with imipramine (CE B, RG 3) (Shrivastava et al. 1994).”
ResultSimhandl, C., Denk, E., & Thau, K. (1993) · Journal of Affective Disorders · doi:10.1016/0165-0327(93)90057-q · Cited by 67
Kocsis, J. H., Thase, M. E., Trivedi, M. H., Shelton, R. C., Kornstein, S. G., Nemeroff, C. B., Friedman, E. S., Gelenberg, A. J., Dunner, D. L., Hirschfeld, R. M. A., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0706 · Cited by 67 · cited 2×
“Fluoxetine responders were not randomly assigned but continued taking fl uoxetine in order to maintain the blind during the maintenance study (Kocsis et al. 2007).”
BackgroundTerra, J.-L., & Montgomery, S. (1998) · PubMed · Cited by 66
Management of recurrent depression.
Kupfer, D. J. (1993) · PubMed · Cited by 65
Reynolds, C. F., Perel, J. M., Frank, E., Cornes, C., Miller, M. D., Houck, P. R., Mazumdar, S., Stack, J. A., Pollock, B. G., Dew, M. A., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.8.1177 · Cited by 65 · cited 2×
“The effi cacy and safety of nortriptyline in preventing recurrence of major depressive episodes in patients older than 59 were well determined in a 3-year placebo-controlled maintenance study of nortriptyline combined with psychotherapy and nortriptyline monotherapy (Reynolds et al. 1999a).”
BackgroundResultGao, K., Kemp, D. E., Fein, E., Wang, Z., Fang, Y., Ganocy, S. J., & Calabrese, J. R. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09r05535gre · Cited by 63 · cited 1×
“SGA and their negative effect on metabolic function, weight gain as well as tardive dyskinesia should be taken under consideration and are criticized as underestimated in prescribing this group of medication also in unipolar depression (Gao et al. 2011).”
BackgroundEffects of Maintenance Electroconvulsive Therapy on Cognitive Functions
Vothknecht, S., Kho, K. H., van Schaick, H. W., Zwinderman, A. H., Middelkoop, H. A. M., & Blansjaar, B. A. (2003) · Journal of Ect · doi:10.1097/00124509-200309000-00007 · Cited by 62 · cited 1×
“A recent review listed six prospective naturalistic studies (Wijkstra et al. 2000; Datto et al. 2001; Swoboda et al. 2001; Rami-Gonzalez et al. 2003; Vothknecht et al. 2003; Rami et al. 2004; Odeberg et al. 2008) and two RCTs (Kellner et al. 2006; Navarro et al. 2008) examining continuation-…”
BackgroundKasper, S. F., Volz, H., Möller, H. ‐., Dienel, A., & Kieser, M. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.06.006 · Cited by 61 · cited 1×
“The effi cacy and safety of HYPERICUM EXTRACT WS 5570 in preventing relapse/recurrence during 6 months ’ continuation treatment and 12-month long-term maintenance treatment after recovery from an episode of recurrent depression was investigated in a large RCT with 426 patients (Kasper et al. 2008).”
MethodSelf-citationThe lithiumeter: a measured approach
Malhi, G. S., Tanious, M., & Gershon, S. (2011) · Bipolar Disorders · doi:10.1111/j.1399-5618.2011.00918.x · Cited by 60
Kornstein, S. G., Bose, A., Li, D., Saikali, K. G., & Gandhi, C. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1115 · Cited by 60 · cited 1×
“…van den Broek et al. 2006), SSRIs (citalopram (Hochstrasser et al. 2001; Klysner et al. 2002)) (CE A, RG 1), escitalopram (Rapaport et al. 2004; Kornstein et al. 2006)) (CE A, RG 1), fl uoxetine (Gilaberte et al. 2001; Keller et al. 2007)) (CE A, RG 2), fl uvoxamine (Terra and Montgomery 1998)…”
BackgroundFluoxetine in the Prevention of Depressive Recurrences: A Double-Blind Study
Gilaberte, I., Montejo, A. L., de la Gandara, J., Perez-Sola, V., Bernardo, M., Massana, J., Martin-Santos, R., Santiso, A., Noguera, R., Casais, L., et al. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200108000-00009 · Cited by 58 · cited 1×
“…et al. 2001; Klysner et al. 2002)) (CE A, RG 1), escitalopram (Rapaport et al. 2004; Kornstein et al. 2006)) (CE A, RG 1), fl uoxetine (Gilaberte et al. 2001; Keller et al. 2007)) (CE A, RG 2), fl uvoxamine (Terra and Montgomery 1998) (CE A, RG 2), paroxetine (Montgomery and Dunbar…”
Odeberg, H., Rodriguez-Silva, B., Salander, P., & Mårtensson, B. (2008) · The Journal of ECT · doi:10.1097/yct.0b013e318177275d · Cited by 57 · cited 1×
“…studies (Wijkstra et al. 2000; Datto et al. 2001; Swoboda et al. 2001; Rami-Gonzalez et al. 2003; Vothknecht et al. 2003; Rami et al. 2004; Odeberg et al. 2008) and two RCTs (Kellner et al. 2006; Navarro et al. 2008) examining continuation- (C-ECT) or maintenanceECT (M-ECT) (Petrides et…”
BackgroundEvidence Report: Treatment of Depression - Newer Pharmacotherapies
(1999) · Pharmacopsychiatry · doi:10.1055/s-2007-991098 · Cited by 57
Dawson, R., Lavori, P. W., Coryell, W. H., Endicott, J., & Keller, M. B. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(97)00181-x · Cited by 54 · cited 1×
“Even though no defi nite recommendation can be given as to when prophylactic therapy should be initiated, it is clearly indicated in situations associated with a high risk of recurrence (Dawson et al. 1998; Angst 1999; Paykel 2001) (Table II).”
Backgroundvan den Broek, W. W., Birkenhäger, T. K., Mulder, P. G. H., Bruijn, J. A., & Moleman, P. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0213 · Cited by 54
Suicidal Behavior On and Off Lithium Prophylaxis in a Group of Patients With Prior Suicide Attempts
Bocchetta, A., Ardau, R., Burrai, C., Chillotti, C., Quesada, G., & Del Zompo, M. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199810000-00006 · Cited by 53 · cited 1×
“Furthermore, clinical fi ndings suggest that the antisuicidal property of lithium acts independently of its “ classical ” episode preventive effect (Schou 1997; Bocchetta et al. 1998; Grof 1998).”
BackgroundAltamura, A. C., & Percudani, M. (1993) · PubMed · Cited by 53
Bauer, M., Whybrow, P. C., Angst, J., Versiani, M., Möller, H., Allain, H., Andersson, I., Aayuso-Gutierrez, J., Bladwin, D., & Bech, P. (2009) · Cited by 52
Self-citationBauer, M., Priebe, S., Berghöfer, A., Bschor, T., Kiesslinger, U., & Whybrow, P. C. (2001) · Journal of Affective Disorders · doi:10.1016/s0165-0327(00)00215-9 · Cited by 51 · cited 1×
“Besides the established treatment options, adjunctive treatment with thyroid hormone ( L -thyroxine) in supraphysiological doses has also been suggested for maintenance treatment of patients with prophylaxisresistant depression (Bauer et al. 2001).”
BackgroundSelf-citationTerra, J. L., & Montgomery, S. A. (1998) · International Clinical Psychopharmacology · doi:10.1097/00004850-199803000-00001 · Cited by 51
Keller, M. B., Trivedi, M. H., Thase, M. E., Shelton, R. C., Kornstein, S. G., Nemeroff, C. B., Friedman, E. S., Gelenberg, A. J., Kocsis, J. H., Dünner, D. L., et al. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.04.040 · Cited by 49 · cited 1×
“…Klysner et al. 2002)) (CE A, RG 1), escitalopram (Rapaport et al. 2004; Kornstein et al. 2006)) (CE A, RG 1), fl uoxetine (Gilaberte et al. 2001; Keller et al. 2007)) (CE A, RG 2), fl uvoxamine (Terra and Montgomery 1998) (CE A, RG 2), paroxetine (Montgomery and Dunbar 1993) (CE A, RG 1) and…”
Cox, G. R., Fisher, C. A., De Silva, S., Phelan, M., Akinwale, O. P., Simmons, M. B., & Hetrick, S. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007504.pub2 · Cited by 48 · cited 1×
“A Cochrane review on this topic summarizes that there is limited evidence that continued medication is more effective than placebo in preventing new episodes (Cox et al. 2012).”
BackgroundHas the Effectiveness of Lithium Changed? Impact of the Variety of Lithium's Effects
Grof, P. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00023-2 · Cited by 48 · cited 1×
“Furthermore, clinical fi ndings suggest that the antisuicidal property of lithium acts independently of its “ classical ” episode preventive effect (Schou 1997; Bocchetta et al. 1998; Grof 1998).”
BackgroundWijkstra, J., Nolen, W. A., Algra, A., Van Vliet, I. M., & Kahn, R. S. (2000) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2000.102006454.x · Cited by 48 · cited 1×
“A recent review listed six prospective naturalistic studies (Wijkstra et al. 2000; Datto et al. 2001; Swoboda et al. 2001; Rami-Gonzalez et al. 2003; Vothknecht et al. 2003; Rami et al. 2004; Odeberg et al. 2008) and two RCTs (Kellner et al. 2006; Navarro et al. 2008) examining continuation-…”
BackgroundPattern of cognitive dysfunction in depressive patients during maintenance electroconvulsive therapy
Rami-González, L., Salamero, M., Boget, T., Catalán, R., FERRER, J., & Bernardo, M. (2003) · Psychological Medicine · doi:10.1017/s003329170200702x · Cited by 47 · cited 1×
“A recent review listed six prospective naturalistic studies (Wijkstra et al. 2000; Datto et al. 2001; Swoboda et al. 2001; Rami-Gonzalez et al. 2003; Vothknecht et al. 2003; Rami et al. 2004; Odeberg et al. 2008) and two RCTs (Kellner et al. 2006; Navarro et al. 2008) examining continuation-…”
BackgroundPerahia, D. G. S., Maina, G., Thase, M. E., Spann, M. E., Wang, F., Walker, D. J., & Detke, M. J. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04756 · Cited by 47 · cited 1×
“Some patients fi nd that a single daily dose facilitates long-term treatment adherence and A, RG 2) and duloxetine (Perahia et al. 2009; Kelin et al. 2010) (CE A, RG 2) and vortioxetine (Boulenger et al. 2012) (CE B, RG 3) are effective in preventing recurrence of depression.”
BackgroundEvidenzbasierte Therapie der Depression: Die S3-Leitlinie unipolare Depression
Härter, M. C., Klesse, C., Bermejo, I., Bschor, T., Gensichen, J., Harfst, T., Hautzinger, M., Kolada, C., Kopp, I., Kühner, C., et al. (2010) · Der Nervenarzt · doi:10.1007/s00115-010-3084-7 · Cited by 46
A Consensus Statement for Safety Monitoring Guidelines of Treatments for Major Depressive Disorder
Dodd, S., Malhi, G. S., Tiller, J., Schweitzer, I., Hickie, I., Khoo, J. P., Bassett, D. L., Lyndon, B., Mitchell, P. B., Parker, G., et al. (2011) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048674.2011.595686 · Cited by 45 · cited 1×
“The consideration of the patient ’ s course of illness and treat- ence), monitor pharmacotherapy for safety and to detect breakthrough symptoms early (Rush 1999; Dodd et al. 2011).”
BackgroundSSRIs, bone mineral density, and risk of fractures — a review
Schwan, S., & Hallberg, P. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.05.001 · Cited by 44 · cited 1×
“However, there is recent concern about the capacity of SSRI antidepressants to reduce bone mineral density, with long-term implications including increased fracture risk (Schwan and Hallberg 2009; Williams et al. 2008).”
BackgroundHead to head comparisons as an alternative to placebo-controlled trials
Vieta, E., & Cruz, N. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.11.011 · Cited by 44 · cited 1×
“However, lack of superiority does not necessarily imply equivalent effi cacy (Vieta and Cruz 2012).”
BackgroundMaintenance study for adolescent depression
Cheung, A., Kusumakar, V., Kutcher, S., Dubo, E., Garland, J., Weiss, M., Kiss, A., & Levitt, A. (2008) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.0001 · Cited by 44 · cited 1×
“In recent years several studies have been performed to examine effi - cacy of antidepressants and their potential to prevent new depressive episodes after remission or response in children and adolescents (Brent et al. 2008; Cheung et al. 2008; Emslie et al. 2008).”
BackgroundA systematic review of the clinical relevance of repetitive transcranial magnetic stimulation
Lepping, P., Schönfeldt‐Lecuona, C., Sambhi, R. S., Lanka, S. V. N., Lane, S., Whittington, R., Leucht, S., & Poole, R. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12276 · Cited by 44 · cited 1×
“TMS is one of the few fundamentally new treatments introduced into psychiatric practice for a considerable number of years (Gaynes et al. 2014; Lepping et al. 2014).”
BackgroundBschor, T., Berghöfer, A., Ströhle, A., Kunz, D., Adli, M., Müller-Oerlinghausen, B., & Bauer, M. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200208000-00016 · Cited by 42 · cited 1×
“The use of lithium as maintenance therapy for recurrent unipolar depression is well established (CE A, RG 2) (Schou 1997; Davis et al. 1999; Bauer et al. 2000, 2014; Coppen 2000; Paykel 2001; Bschor et al. 2002; Davis 2006).”
BackgroundSelf-citationLong-term lithium and mortality
Coppen, A. J., Standish‐Barry, H. M. A. S., Bailey, J., Houston, G., Silcocks, P. B. S., & Hermon, C. (1990) · The Lancet · doi:10.1016/0140-6736(90)91232-y · Cited by 41 · cited 1×
“Over the past decade, evidence has accumulated from retrospective and prospective studies that longterm lithium prophylaxis may reduce suicide risk and even normalize the high mortality rate (CE B, RG 3) (Coppen et al. 1990; M ü ller-Oerlinghausen et al. 1992, 1994; Tondo et al. 1997; Schou 2000).”
BackgroundNew developments in the treatment of depression.
Montgomery, S. (1999) · PubMed · Cited by 40
Lithium in unipolar depression and the prevention of suicide.
Coppen, A. J. (2000) · PubMed · Cited by 36
Suicidal Behavior and Prophylactic Lithium Treatment of Major Mood Disorders: A Review of Reviews
Schou, M. (2000) · Suicide and Life-Threatening Behavior · doi:10.1111/j.1943-278x.2000.tb00993.x · Cited by 35 · cited 1×
“Over the past decade, evidence has accumulated from retrospective and prospective studies that longterm lithium prophylaxis may reduce suicide risk and even normalize the high mortality rate (CE B, RG 3) (Coppen et al. 1990; M ü ller-Oerlinghausen et al. 1992, 1994; Tondo et al. 1997; Schou 2000).”
BackgroundSchüle, C., Zwanzger, P., Baghai, T. C., Mikhaiel, P., Thoma, H., Möller, H., Rupprecht, R., & Padberg, F. (2003) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(02)00101-2 · Cited by 34 · cited 1×
“Additional antidepressant medication as maintenance treatment after acute rTMS also seems to be a reasonable advice (Schule et al. 2003).”
BackgroundSelf-citationRami, L., Bernardo, M., Boget, T., Ferrer, J., Portella, M. J., Gil-Verona, J. A., & Salamero, M. (2004) · Journal of Neuropsychiatry · doi:10.1176/jnp.16.4.465 · Cited by 33 · cited 1×
“…prospective naturalistic studies (Wijkstra et al. 2000; Datto et al. 2001; Swoboda et al. 2001; Rami-Gonzalez et al. 2003; Vothknecht et al. 2003; Rami et al. 2004; Odeberg et al. 2008) and two RCTs (Kellner et al. 2006; Navarro et al. 2008) examining continuation- (C-ECT) or maintenanceECT…”
BackgroundImpact of Maintenance ECT on Concentration and Memory
Datto, C. J., Levy, S. C., Miller, D. S., & Katz, I. R. (2001) · Journal of Ect · doi:10.1097/00124509-200109000-00004 · Cited by 30 · cited 1×
“A recent review listed six prospective naturalistic studies (Wijkstra et al. 2000; Datto et al. 2001; Swoboda et al. 2001; Rami-Gonzalez et al. 2003; Vothknecht et al. 2003; Rami et al. 2004; Odeberg et al. 2008) and two RCTs (Kellner et al. 2006; Navarro et al. 2008) examining continuation-…”
BackgroundMüller-Oerlinghausen, B. (1999) · PubMed · Cited by 30
Evidenzbasierte Therapie der Depression: Die S3-Leitlinie unipolare Depression
Härter, M. C., Klesse, C., Bermejo, I., Bschor, T., Gensichen, J. S., Harfst, T., Hautzinger, M., Kolada, C., Kopp, I., Kühner, C., et al. (2010) · Der Nervenarzt · Cited by 29
Hegerl, U., Allgaier, A., Henkel, V., & Mergl, R. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.05.015 · Cited by 29 · cited 1×
“Consequently establishing the proof of effi cacy in a methodologically comparable way to psychopharmacological interventions (doubleblind, placebo-controlled trials) has been impossible (Hegerl et al. 2011).”
BackgroundThase, M. E., Gelenberg, A. J., Kornstein, S. G., Kocsis, J. H., Trivedi, M. H., Ninan, P. T., Li, T., Pedersen, R., & Keller, M. B. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.07.009 · Cited by 28 · cited 1×
“…experiencing a recurrence was 71.9% for venlafaxine and 55.8% for fl uoxetine across 24 months of maintenance treatment without showing signifi cant superiority of venlafaxine; however, a signifi cant treatment-by-time interaction showing superiority of venlafaxine was observed (Thase et al. 2011).”
BackgroundInfluentialContinuation and Maintenance Pharmacotherapy for Unipolar and Bipolar Mood Disorders
Solomon, D. A., & Bauer, M. S. (1993) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(18)30163-1 · Cited by 26 · cited 2×
“Due to the methodologically challenges to validly conduct them (Licht 2013), there is only a relatively small number of studies that have directly compared different medications for maintenance treatment in recurrent unipolar depression (Solomon and Bauer 1993).”
BackgroundSelf-citationStrategies and tactics in the management of maintenance treatment for depressed patients.
Rush, A. J. (1999) · PubMed · Cited by 22
Severus, E., & Bauer, M. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-34 · Cited by 22 · cited 1×
“…function (e.g., blood calcium and, if elevated, also parathyroid hormone) and renal function (creatinine, eGFR) (e.g., once or twice a year) is recommended (American Psychiatric Association 1994; Berger et al. 2013; Bschor 2014; Livingstone and Rampes 2006; Schou 1997; Severus and Bauer 2013).”
BackgroundSelf-citationMarraccini, R. L., Reynolds, C. F., Houck, P. R., Miller, M. D., Frank, E., Perel, J. M., Cornes, C. L., Mazumdar, S., & Kupfer, D. J. (1999) · International Journal of Geriatric Psychiatry · doi:10.1002/(sici)1099-1166(199912)14:12<1014::aid-gps52>3.0.co;2-i · Cited by 18 · cited 1×
“Except for a consistent increase in heart rate and some dry mouth, no other adverse events were detected in comparison with placebo (Marraccini et al. 1999).”
Kim, H. R., Delva, N. J., & Lawson, J. S. (1990) · The Canadian Journal of Psychiatry · doi:10.1177/070674379003500201 · Cited by 16 · cited 2×
“…with antidepressants showed no conclusive advantage for lithium in the prophylaxis of unipolar illness (Souza and Goodwin 1991; Cipriani et al. 2006), while the combination treatment of lithium with an antidepressant proved superior to lithium alone or the antidepressant alone (Kim et al. 1990).”
BackgroundExploratory meta-analysis on deep brain stimulation in treatment-resistant depression
Smith, D. F. (2013) · Acta Neuropsychiatrica · doi:10.1017/neu.2014.22 · Cited by 14 · cited 1×
“DBS is being evaluated as an option for treatment resistant major depressive episodes (Smith 2014).”
BackgroundTint, A., Haddad, P. M., & Anderson, I. M. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107087488 · Cited by 13 · cited 1×
“Data from a RCT showed that discontinuation symptoms are more common with a shorter acting SSRI, such as paroxetine, than with the longer acting agent, such as fl uoxetine (Rosenbaum et al. 1998; Tint et al. 2008).”
BackgroundLicht, R. W. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.12.009 · Cited by 11 · cited 2×
“Due to the methodologically challenges to validly conduct them (Licht 2013), there is only a relatively small number of studies that have directly compared different medications for maintenance treatment in recurrent unipolar depression (Solomon and Bauer 1993).”
BackgroundKelin, K., Berk, M., Spann, M., Sagman, D., Raskin, J., Walker, D., & Perahia, D. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02374.x · Cited by 11 · cited 1×
“Some patients fi nd that a single daily dose facilitates long-term treatment adherence and A, RG 2) and duloxetine (Perahia et al. 2009; Kelin et al. 2010) (CE A, RG 2) and vortioxetine (Boulenger et al. 2012) (CE B, RG 3) are effective in preventing recurrence of depression.”
BackgroundBerger, M., Riedel, M. J., Tomova, N., Obermeier, M., Seemüller, F., Dittmann, S., Mœller, H., & Severus, E. (2013) · International Journal of Bipolar Disorders · doi:10.1186/2194-7511-1-7 · Cited by 8 · cited 1×
“…function (e.g., blood calcium and, if elevated, also parathyroid hormone) and renal function (creatinine, eGFR) (e.g., once or twice a year) is recommended (American Psychiatric Association 1994; Berger et al. 2013; Bschor 2014; Livingstone and Rampes 2006; Schou 1997; Severus and Bauer 2013).”
BackgroundSelf-citationFacing two demons: lithium therapy from a patient’s point of view
Selo, M. (2013) · CRC Press eBooks · doi:10.3109/9780203007051-13 · Cited by 7 · cited 1×
“The use of lithium as maintenance therapy for recurrent unipolar depression is well established (CE A, RG 2) (Schou 1997; Davis et al. 1999; Bauer et al. 2000, 2014; Coppen 2000; Paykel 2001; Bschor et al. 2002; Davis 2006).”
BackgroundMosolov, S. N., Mv, K., Mg, U., Misionzhhnik, E. I., & Ryzhov, A. M. (1997) · PubMed · Cited by 2
Research works printed but not linked: 27
- American Psychiatric Association, 2000, Am J Psychiatry, 157, 1
- Anderson IM, 2000, J Psychopharmacol, 14, 3, 10.1177/026988110001400101 · DOI · Paper page
- Angst J, 1999, J Clin Psychiatry, 60, 5
- Beaulieu S, 2012, Ann Clin Psychiatry, 24, 38
- Bond DJ, 2012, Ann Clin Psychiatry, 24, 23
- Burgess S, 2001, Cochrane Database Syst Rev, CD003013
- Cipriani A, 2006, Cochrane Database Syst Rev, CD003492
- Coppen A, 2000, J Clin Psychiatry, 61, 52
- Cox GR, 2012, Cochrane Database Syst Rev, 11, D007504
- Kupfer DJ, 1993, J Clin Psychiatry, 54, 29
- Lejoyeux M, 1997, J Clin Psychiatry, 58, 11
- McIntyre RS, 2012, Ann Clin Psychiatry, 24, 69
- McIntyre RS, 2012, Ann Clin Psychiatry, 24, 2
- Mohr DC, 2012, J Am Med Assoc, 307, 2278
- Montgomery SA, 1999, J Clin Psychiatry, 60, 10
- Mosolov SN, 1997, Zh Nevrol Psikhiatr Im S S Korsakova, 97, 30
- Pacchiarotti I, 2013, Am J Psychiatry
- Placidi GF, 1986, J Clin Psychiatry, 47, 490
- Ramasubbu R, 2012, Ann Clin Psychiatry, 24, 82
- Ramasubbu R, 2012, Ann Clin Psychiatry, 24, 91
- Rosenbluth M, 2012, Ann Clin Psychiatry, 24, 56
- Rush AJ, 1999, J Clin Psychiatry, 60, 21
- Schaffer A, 2012, Ann Clin Psychiatry, 24, 6
- Taylor MJ, 2013, Cochrane Database Syst Rev, 5, CD003382
- Thase ME, 1999, J Clin Psychiatry, 60, 3
- Tint A, 2008, J Psychopharmacol, 22, 330, 10.1177/0269881107081550 · doi:10.1177/0269881107081550 · Paper page
- Wilkinson P, 2012, Cochrane Database Syst Rev, 11, D006727
Cited by
Marx, W., Penninx, B. W. J. H., Solmi, M., Furukawa, T. A., Firth, J., Carvalho, A. F., & Berk, M. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00454-1 · Cited by 768
“Different guidelines make specific recommendations regarding first-line and second-line treatments for MDD and maintenance treatment across age groups and special populations 149,168,169 .”
Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz039 · Cited by 606
Exercise can improve sleep quality: A systematic review and meta-analysis
Banno, M., Harada, Y., Taniguchi, M., Tobita, R., Tsujimoto, H., Tsujimoto, Y., Kataoka, Y., & Noda, A. (2018) · PeerJ · doi:10.7717/peerj.5172 · Cited by 246
Sim, K., Lau, W. K., Sim, J., Sum, M. Y., & Baldessarini, R. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv076 · Cited by 218
Sforzini, L., Worrell, C., Kose, M., Anderson, I. M., Aouizerate, B., Arolt, V., Bauer, M., Baune, B. T., Blier, P., Cleare, A. J., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01381-x · Cited by 214
Self-citation
Metadata
- Authors
- Bauer, M., Severus, E., Köhler, S., Whybrow, P. C., Angst, J., Möller, H.-J., & on behalf of the Wfsbp Task Force on Treatment Guidelines for Unipolar Depressive Disorders
- Affiliations
- Technische Universität Dresden (DE)
- Charité – Universitätsmedizin Berlin (DE)
- University of California, Los Angeles (US)
- University of Zurich (CH)
- Ludwig-Maximilians-Universität München (DE)
- Corresponding author
- Bauer, Michael
- Venue
- The World Journal of Biological Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2015-02-13
- Volume
- 16
- Issue
- 2
- Pages
- 76-95
- ISSN
- 1562-2975 (ISSN-L)
- 1814-1412
- OpenAlex
- W2171166616
- Semantic Scholar
- 08abea4813fc2772a35482f1e6e14c9ffdcdc28f
- Cited by
- 199
- References
- 200
- Citations by year
- 2026: 10 · 2025: 7 · 2024: 19 · 2023: 15 · 2022: 26 · 2021: 18 · 2020: 25 · 2019: 22 · 2018: 20 · 2017: 24 · 2016: 8 · 2015: 5
- FWCI
- 13.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The World Journal of Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- GlaxoSmithKline
- Bundesministerium für Bildung und Forschung
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- major depressive disorder, maintenance therapy, biological treatment, antidepressants, hormone therapy, electroconvulsive therapy, brain stimulation, children and adolescents, older adults, treatment guidelines
- MeSH terms
- Quetiapine Fumarate, Antidepressive Agents, Biological Psychiatry, Carbamazepine, Major Depressive Disorder, Dibenzothiazepines, Drug Therapy, Combination, Electroconvulsive Therapy, Humans, Lithium, Plant Extracts, Psychotherapy, Antipsychotic Agents, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.